Grant ID

98-RC-305-3

Illness

Bipolar Disorder

Primary Drug/Intervention

Retigabine

Primary Dosage

600 mg and 1200 mg

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Walden

Sample Size

10

Duration of Study Period for Each Subject

N/A

Outcome Measurements

N/A

Results

A small number of patients with acute mania showed beneficial effects with retigabine. However 70 percent of patients discontinued treatment due to side effects or lack of efficacy.

Publication

N/A

Link

N/A

PI Name

Joerg Walden

Degree

MD

Center

N/A

Institution

N/A

Address

City or Town

Frieburg

State or Province

N/A

Zip or Postal Code

N/A

Country

Germany

Email Address

JOERG_WALDEN@psyallg.ukl.uni-freiburg.de